Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company MinervaX ApS
DescriptionVaccine containing a single fusion protein as an antigen against the N-terminal regions of the Group B Streptococcus surface proteins Rib and alpha
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationStreptococcus
Indication DetailsPrevent group B Streptococcus infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today